Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report
Yan Teng,Mingyang Ren,Xianhong Yang,Wei Lu,Xiaohua Tao
DOI: https://doi.org/10.2147/ppa.s451007
2024-02-23
Patient Preference and Adherence
Abstract:Yan Teng, Mingyang Ren, Xianhong Yang, Wei Lu, Xiaohua Tao Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, 310014, People's Republic of China Correspondence: Xiaohua Tao, Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, 310014, People's Republic of China, Tel +86-13505811700, Email Background: Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being the most commonly affected site. Its treatment depends on the site(s) of mucosal involvement and disease severity. Patients and Methods: A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile. Results: The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement. Conclusion: Abrocitinib is a promising agent for the treatment of MMP with oral involvement. Keywords: abrocitinib, mucous membrane pemphigoid, JAK inhibitor Mucous membrane pemphigoid (MMP), a rare autoimmune, vesiculous, erosive disease, is characterized by post-bullous erosion of the mucous membranes, including that of the oral, ocular, laryngeal, and skin, 1 with the oral cavity being the most commonly affected site. Limited cutaneous involvement, typically localized to the head, neck, or upper trunk, is also observed. Patients with extensive oral involvement or those who do not respond adequately to local therapy are good candidates for systemic treatment. Long-term systemic corticosteroids or immunosuppressive agents are first prescribed. However, these agents have their limitations due to long-term side effects. Herein, we reported a case of MMP with predominant oral involvement that was successfully treated by abrocitinib, which is a highly selective JAK-1 inhibitor. A 62-year-old female was referred to our dermatological department with a 6 months history of progressive oral erosion and skin erythema and blisters. The severe oral pain caused feeding disorders, leading to weight loss. Physical examination revealed that post-blistering erosions were mainly present on the left palatal mucosa (Figure 1a) and several small fluid-filled blisters and erythema were scattered on the scalp, trunk, and limbs. Histopathology of a blister on the scalp revealed that there was a cleavage between the epidermis and dermis with a few eosinophils and lymphocyte infiltrations (Figure 2a). Direct immunofluorescence testing found linear immunoglobulin G (IgG) and C3 deposits along the dermoepidermal junction (Figure 2b). A serological examination revealed elevated anti-BP180 levels (81.16 U/mL) and normal BP230 levels on enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Medizinische Labordiagnostika AG, Germany). Other laboratory findings, including routine blood analysis; urine analysis; liver, kidney, and thyroid function tests; erythrocyte sedimentation rate; antinuclear antibodies; and Rheumatoid factor were within the normal range. Based on these findings, a final diagnosis of MMP was made. Figure 1 Mucous membrane pemphigoid with the oral predominant response to abrocitinib therapy. (a) before the abrocitinib therapy. (b) Two weeks later after the abrocitinib therapy. (c) Four weeks later after the abrocitinib therapy. Figure 2 (a) A cleavage between the epidermis and dermis with a few infiltrations of eosinophils and lymphocytes. (b) Direct immunofluorescence showed IgG was deposited linearly in the basement membrane zone. For 2 months, the patient was placed on a high-potency topical corticosteroid and topical tacrolimus; however, no significant improvements in the symptoms were noted. The patient refused to receive the treatment of systemic corticosteroid or immunosuppressive agents for their long-term adverse events and she also refused the dupilumab therapy for its subcutaneous injection administration. After a routine blood examination, biochemistry analysis, coagulation function tests, and chest computed tomography (CT) to rule out severe infection, coagulation dysfunction, hepatic failure, renal disorder, and tuberculosis, she was prescribed 100 mg of abrocitinib per day. After 3 days of abrocitinib therapy, she reported significant improvement in pain. Two wee -Abstract Truncated-
medicine, general & internal